IL-4, IL-13, and IL-33 Transcriptional Responses in Human Eosinophils and Mast Cells

Central Finding

IL-33 drives the broadest transcriptional response in both cell types, signals through NF-κB/AP-1 (not STAT6), and massively induces downstream biologic drug targets (IL-13, IL-5) while paradoxically downregulating others (PTGDR2, SIGLEC8).

Cell-Type Divergence

Over 90% of DEGs for each cytokine are cell-type-specific, with zero TF overlap in top regulators: STAT6 drives IL-4/IL-13 in eosinophils but SPI1/PU.1 and AP1 replace it in mast cells.

IL-4/IL-13 Asymmetry

IL-13 consistently induces ~50% fewer DEGs than IL-4 with a pronounced deficit in gene down-regulation, and has virtually no unique transcriptional program in mast cells (15 genes, 3.7%).

Why Re-analyze?

The original paper deposited this RNA-seq data as supplementary to mouse model and clinical trial analyses, leaving the in vitro human transcriptomics largely unexplored. This re-analysis applies modern pathway enrichment, TF activity inference, and gene regulatory network methods to extract the full biological signal.

Experimental Caveat

Eosinophils were treated overnight while mast cells were treated for 48 hours, and each cell type comes from different donors. These differences partially confound direct cross-cell-type comparisons and should be considered when interpreting divergent responses.

Treatment Dominates Variation

Treatment is the dominant source of variation in both cell types. IL-33 is qualitatively distinct from IL-4/IL-13 on PC2, consistent with its use of a different receptor (ST2) and signaling pathway (NF-κB vs STAT6).

IL-4/IL-13 Overlap

IL-4 and IL-13 samples cluster together in eosinophils, consistent with shared IL-4Rα/STAT6 signaling. In mast cells, they show more separation, hinting at differential receptor engagement.

Outlier Handling

MC sample 1527576 (Donor 6 control) had 201M total counts — 14× the median library size — and was excluded. Donor 6 retains 6 samples across the remaining conditions (IL-4, IL-13, IL-33).

IL-33 Broadest Response

IL-33 drives the most DEGs in both cell types (850 eos, 1,334 MC) despite signaling through a completely different receptor (ST2) and pathway (NF-κB) than IL-4/IL-13 (IL-4Rα/STAT6).

IL-33 → IL-13 Feedback

IL13 is the top IL-33-upregulated gene in mast cells (log₂FC = +10.0), suggesting a positive-feedback amplification circuit: IL-33 → mast cell IL-13 release → IL-4Rα signaling in neighboring cells.

IL-4 > IL-13 Asymmetry

IL-13 induces ~50% fewer DEGs than IL-4 in both cell types (376 vs 664 in eos, 402 vs 646 in MC), with a pronounced deficit in down-regulation. This consistent pattern suggests a fundamental difference in IL-4 vs IL-13 signaling capacity.

3-Way Convergence 3.4× Greater in MC

269 mast cell genes (17%) are regulated by all three cytokines vs only 78 (5.2%) in eosinophils. This convergence may be driven by IL-33 → autocrine IL-13 creating secondary STAT6 overlap with the IL-4/IL-13 pathway.

IL-13 Near-Zero Unique Program in MC

Only 15 mast cell DEGs (3.7%) are unique to IL-13 — the smallest category by far. This is consistent with low IL-13Rα1 expression in mast cells and suggests IL-13 signaling is almost entirely redundant with IL-4 in this cell type.

IL17RB Feedforward Loop Novel

IL-4 uniquely upregulates IL17RB (the IL-25 receptor) in eosinophils, creating a feedforward loop that enhances IL-25 responsiveness. IL-13 does NOT engage this pathway, revealing a fundamental mechanistic divergence between these “redundant” cytokines.

IFN-γ/α response pathways are strongly upregulated in mast cells by all three cytokines (NES = 1.97–2.21, FDR < 0.001) but absent or downregulated in eosinophils — a fundamental cell-type divergence suggesting mast cells activate immune surveillance programs alongside canonical cytokine responses.

KRAS/MAPK signaling is downregulated by IL-13 in eosinophils (NES = -1.43) but upregulated in mast cells (NES = 1.87, FDR = 0.005), indicating fundamentally different downstream MAPK engagement from the same cytokine across cell types.

IL-4-unique genes in eosinophils enrich for IL2_STAT5_SIGNALING (padj = 1.0e-4, OR = 6.1), providing pathway-level evidence that IL-4 engages STAT5-dependent programs via the type I receptor (IL-4Rα/γc) that IL-13 cannot access through the type II receptor alone.

STAT6 Cell-Type Specific

STAT6 is the master regulator of IL-4/IL-13 responses in eosinophils (padj < 0.003) but is NOT significant in mast cells (padj > 0.85). This is consistent with known proteolytic processing of STAT6 in mast cells (Suzuki 2002), representing a fundamental divergence in how the same cytokines are transduced.

MEIS2, a homeobox transcription factor, is the #1 activated TF in eosinophils for IL-4 (delta = 1.035) and also the top TF for IL-33 (delta = 1.22). This TF has not been previously described in the context of type 2 cytokine signaling in eosinophils.

IL-13 produces zero significantly altered TFs in mast cells (FDR < 0.05), the most extreme evidence of its minimal signaling capacity. Combined with only 15 unique DEGs, this supports a model where IL-13 has virtually no independent transcriptional program in mast cells.

Spearman rho is effectively zero for IL-4 (ρ = -0.002) and IL-13 (ρ = -0.002), meaning the genome-wide rank ordering of gene responsiveness is completely uncorrelated between eosinophils and mast cells. Over 90% of DEGs for each cytokine are cell-type-specific, with only 6-8% shared concordant.

IL-33 Shares Most Genes

IL-33 has 152 shared concordant genes — the highest absolute number among the three cytokines — driven by NF-kB/TNFa signaling that operates in both eosinophils and mast cells. It also has the most discordant genes (35), including notable direction reversals in drug targets like ALOX5 and SIGLEC8.

Donor 7 has near-zero or negative correlations with all other donors across ALL cytokines (Spearman ρ: −0.075 to +0.033), suggesting a fundamentally discordant cytokine response phenotype — a potential “non-responder” mast cell phenotype relevant for patient stratification in biologic therapy.

High-variability genes enrich strongly for coagulation cascades (Hallmark COAGULATION padj = 3.3×10⁻⁷ for IL-4, 5.2×10⁻⁹ for IL-13) and ECM remodeling, suggesting that donor-variable responses primarily affect tissue remodeling pathways — consistent with variable airway remodeling outcomes in asthma patients.

EBI3 is the top hub gene in the IL-33-specific module (M1) alongside NFKB2 and TNFRSF9, suggesting an IL-33→NF-κB→EBI3/IL-35 immunoregulatory axis in mast cells. EBI3 encodes the IL-27β/IL-35 subunit — its co-expression with NF-κB targets points to a coordinated program that may dampen or redirect downstream inflammation.

5 of 7 modules are strongly correlated with Donor 7 (|r|=0.62–0.87), confirming that donor heterogeneity overwhelms cytokine effects at the network level. IL-4 and IL-13 fail to organize any detectable co-expression module above donor-driven variation — only IL-33’s strong NF-κB program (M1, r=0.676) rises above the noise.

IL-33 Master Inducer

IL-33 upregulates IL13 (log₂FC = +10.0) and IL5 (+7.4) in mast cells — the very targets of tralokinumab and mepolizumab — suggesting IL-33 signaling generates the cytokines that downstream biologics are designed to neutralize, supporting upstream targeting with anti-IL-33 (itepekimab).

ALOX5 (zileuton target) is downregulated by IL-33 in eosinophils (log₂FC = −1.0) but upregulated in mast cells (+1.1), suggesting IL-33-driven inflammation shifts leukotriene synthesis from eosinophil to mast cell compartments.

PTGDR2/CRTh2 (log₂FC = −2.2), SIGLEC8 (−1.4), and MS4A2 (−1.2) are all downregulated by IL-33 in mast cells, potentially reducing drug target availability and contributing to variable clinical efficacy of CRTh2 antagonists and anti-Siglec-8 therapies.

Axis 1: Cytokine Specificity

IL-33 activates NF-κB/inflammatory programs distinct from IL-4/IL-13's STAT6/JAK-STAT programs. IL-4 engages additional STAT5 signaling via γc that IL-13 cannot.

Axis 2: Cell-Type Divergence

The same cytokine activates fundamentally different genes (>90% non-overlapping) and TFs (zero overlap in top regulators) in eos vs MC. MC uniquely activate IFN and antigen presentation programs.

Axis 3: Regulatory Architecture

STAT6 mediates IL-4/IL-13 in eos; SPI1/PU.1 is the pan-cytokine master regulator in MC; NFKB1/JUN drive IL-33 in both. 90.5% of GRN edges are condition-specific.

Axis 4: Therapeutic Landscape

IL-33 simultaneously induces biologic targets (IL-13, IL-5) and suppresses others (PTGDR2, SIGLEC8), creating a dynamic drug target landscape. Donor variability in cytokine responses may underlie variable biologic efficacy.

Eosinophils were treated overnight while mast cells were treated for 48 hours. Cross-cell-type comparisons are confounded by this difference in treatment duration, and observed divergence may partly reflect temporal rather than cell-intrinsic differences.

Only 2 eosinophil donors limits statistical power and generalizability. Mast cell results (5 donors) are more robust, though Donor 7's outlier behavior affects network analyses. Eosinophil donor heterogeneity analysis was not possible.

TF activities are inferred from CollecTRI regulons, which may be biased toward well-studied TFs. GRN edges are based on prior knowledge, not de novo inference. WGCNA power parameter (17) was chosen for scale-free topology fit; different parameters may yield different module structures.

Key findings (STAT6 absence in mast cells, MEIS2 as eosinophil IL-4 TF, EBI3/IL-35 axis, drug target downregulation by IL-33) require protein-level and functional validation experiments. This analysis is based on transcriptomic data alone.